NCT05969665View on ClinicalTrials.gov

Effect of Monitoring Continuous Glucose Levels and Physical Activity Via Wearables on Cardiovascular Risk Factors

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 7, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Coronary Heart DiseasePhysical ActivityCardiovascular Risk Factors
Interventions
DEVICE

Fitbit Inspire 2

A smartwatch (Fitbit Inspire 2) with its respective app will be worn by the patients in the intervention group for 3 months.

DEVICE

Abbott Freestyle Libre 3

A continuous glucose measuring device (Abbott Freestyle Libre 3) with its respective app will be worn by the patients in the intervention group for 3 months.

Trial Locations (1)

4031

RECRUITING

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER